Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

No longer available 1Completed 1

Sponsor Class

INDUSTRY 2

Study Type

Interventional 1Expanded_access 1

Sponsor

Cancer Type

CNS 2

Conditions

Brain Neoplasms 6Breast Neoplasms 4Recurrence 2Oligodendroglioma 2Meningeal Carcinomatosis 2Glioblastoma 2Astrocytoma 2Triple Negative Breast Neoplasms 1Meningeal Neoplasms 1Melanoma 1Lung Neoplasms 1Glioma 1Carcinoma, Non-Small-Cell Lung 1Carcinoma, Hepatocellular 1

Interventions

Temozolomide 17Radiotherapy 8Surgical Procedures, Operative 6Flucytosine 6vocimagene amiretrorepvec 5IL13-PE38 5Lomustine 4Valacyclovir 3Radiation 3Corticotropin-Releasing Hormone 3Chlorotoxin 3Carmustine 3Bevacizumab 3vorasidenib 2trametinib 2tovorafenib 2regorafenib 2pembrolizumab 2paclitaxel-Angiopep-2 conjugate 2dabrafenib 2Trabedersen 2OKN 007 2Nivolumab 2Everolimus 2Eflornithine 2Drug Delivery Systems 2Carboplatin 2Cancer Vaccines 2Adjuvants, Immunologic 2trastuzumab deruxtecan 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
INDUSTRY × Astrocytoma × paclitaxel-Angiopep-2 conjugate × Clear all
NCT02755987 2016-06-07

Expanded Access to ANG1005 for Individual Patients

Angiochem Inc

No longer available
CNS

Astrocytoma, Oligodendroglioma, Meningeal Carcinomatosis

NCT00539344 2014-07-31

A Phase 1, Open-Label, Dose Escalation Study of ANG1005 in Patients With Malignant Glioma

Angiochem Inc

Phase 1 Completed
63 enrolled
CNS

Astrocytoma, Glioblastoma, Oligodendroglioma, Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon âš¡